

(FINAL/APPROVED)
VIRGINIA BOARD OF PHARMACY
MINUTES OF PUBLIC HEARING TO PLACE CERTAIN CHEMICALS INTO SCHEDULE I

Tuesday, June 13, 2023
Commonwealth Conference Center
Second Floor
Board Room 2

Department of Health Professions
Perimeter Center
9960 Mayland Drive
Henrico, Virginia 23233

CALL TO ORDER: A meeting of the Board of Pharmacy (“Board”) was called to order at 9:04am.

PRESIDING: Dale St. Clair, PharmD, Chairman

MEMBERS PRESENT: William Lee, DPh, Vice Chairman
Cheri Garvin, RPh
Larry Kocot, JD
Sarah Melton, PharmD
Wendy Nash, PharmD
Kristopher Ratliff, DPh
Patricia Richards-Spruill, RPh

MEMBERS ABSENT: Ling Yuan, PharmD

STAFF PRESENT: Caroline D. Juran, RPh, Executive Director
Erin Barrett, JD, Director of Legislative and Regulatory Affairs, DHP
James Rutkowski, Senior Assistant Attorney General
Arne W. Owens, Director, DHP
James Jenkins Jr, RN, Chief Deputy Director, DHP
Sorayah Haden, Executive Assistant
Beth O’Halloran, RPh, Deputy Executive Director
Annette Kelley, MS, CSAC, Deputy Executive Director
Ryan Logan, RPh, Deputy Executive Director
Ellen B. Shinaberry, PharmD, Deputy Executive Director

QUORUM: With 8 members of the Board present, a quorum of the board was established.

PUBLIC COMMENT Dr. St.Clair invited members of the public to offer comment on the subjects.

Pursuant to article § 54.1-3443(D), the Virginia Department of Forensic Science (DFS) identified the following five compounds for recommended inclusion into Schedule I of the Drug Control Act.

The following compound is classified as a synthetic opioid. Compounds of this type have been placed in Schedule I (§ 54.1-3446(1)) in previous legislative sessions.

1. N,N-diethyl-2-[5-nitro-2-(4-propoxybenzyl)-1H-benzimidazol-1-yl]ethanamine (other name: Protonitazene), its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation.

Based on their chemical structures, the following compounds are expected to have hallucinogenic properties. Compounds of this type have been placed in Schedule I (§ 54.1-3446(3)) in previous legislative sessions.

2. 1-(1,3-benzodioxol-5-yl)-2-(cyclohexylamino)butan-1-one (other names: Cybutylone, N-cyclohexyl Butylone), its salts, isomers (optical, position, and geometric), and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.

Based on its chemical structure, the following compound is expected to have depressant properties. Compounds of this type have been placed in Schedule I (§ 54.1-3446(4)) in previous legislative sessions.

3. 8-bromo-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine (other names: Clobromazolam, Phenazolam), its salts, isomers (optical, position, and geometric), and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.

The following compounds are classified as cannabimimetic agents. Compounds of this type have been placed in Schedule I (§ 54.1-3446(6)) in previous legislative sessions.

4. 5-bromo-N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-indazole-3-carboxamide (other name: ADB-5Br-INACA), its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.
5. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-5-bromo-1-butylindazole-3-carboxamide (other name: ADB-5'Br-BUTINACA), its salts, isomers, and salts

of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.

Robyn Weimer from the Department of Forensic Science provided comment indicating that the Department recommends the Board consider placing these chemicals into Schedule I.

ADJOURN:

With all business concluded, the meeting adjourned at 9:12AM.



Caroline Juran, RPh, Executive Director

9/26/2023

Date